Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

OUTLINE: This is a multi-center study. Submit tumor and serum samples for central review * Imatinib 600 mg (orally qd); * Docetaxel 30mg/m2 (4 of 6 weeks);1 cycle = 6 weeks * Evaluate every other cycle Each cycle will begin only when the granulocyte count is \> 1,500/mm3 and the platelet count is \> 100,000/mm3 and any other treatment-related toxicities are \< grade 1. If the toxicity is not resolved to grade 0 or 1 after three weeks, the patient will be withdrawn from the study. For days 8, 15, and 22 patients must have an absolute neutrophil count \> 1,000/mm3 or greater and platelet count \> 75,000/mm3. Imatinib mesylate can be administered if platelets \>20,000 and ANC \>500. ECOG performance status 0 or 1 Hematopoietic:· * ANC \> 1,500/mm3· * Platelets \> 100,000 mm3· * Hgb \> 8g/dl Hepatic:· * Albumin\>3gm/dL· * Total bilirubin \< ULN· * Maximum Alk Phos: \>2.5x but \< 5x ULN Renal:· * Creatinine \< 1.5 x ULN·(by Cockroft and Gault) Cardiovascular:· * No grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months prior to beginning protocol therapy) Pulmonary:· * Not specified